How should elevated triglycerides be managed in an adult?

Management of Elevated Triglycerides in Adults

The management of elevated triglycerides must be stratified by severity: for triglycerides 150-499 mg/dL, initiate lifestyle modifications and statin therapy based on ASCVD risk; for triglycerides 500-999 mg/dL, add aggressive dietary fat restriction (20-25% of calories) and consider fibrates or prescription omega-3 fatty acids; for triglycerides ≥1,000 mg/dL, implement extreme dietary fat restriction (<10-15% of calories) and start fibrate therapy immediately to prevent acute pancreatitis. 1

Initial Assessment and Risk Stratification

First, obtain fasting triglyceride levels for accurate diagnosis—non-fasting measurements are inadequate 2. Screen adults at least every 5 years as part of a standard lipid panel 2.

Immediately evaluate for secondary causes before assuming primary hypertriglyceridemia 2, 1:

• Endocrine disorders: Uncontrolled diabetes (most common), hypothyroidism, Cushing's syndrome
• Medications: Thiazide diuretics, beta-blockers, estrogen therapy, corticosteroids, protease inhibitors, atypical antipsychotics, isotretinoin
• Lifestyle factors: Excessive alcohol intake, high simple carbohydrate/sugar consumption, obesity
• Renal disease: Nephrotic syndrome, chronic kidney disease
• Liver disease: Hepatic steatosis

If diabetes is present with triglycerides ≥1,000 mg/dL and poor glycemic control, treat hyperglycemia first, then reassess triglycerides 1.

Management by Triglyceride Level

Mild to Moderate Hypertriglyceridemia (150-499 mg/dL)

Lifestyle Interventions:

• Diet composition: Moderate-fat diet (30-35% of total calories from fat), emphasizing replacement of refined carbohydrates with unsaturated fatty acids 1
• Eliminate: Added sugars, sugar-sweetened beverages
• Restrict: Alcohol consumption (ideally eliminate)
• Increase: Soluble fiber intake to >10 g/day 1
• Weight loss: If overweight/obese, as this independently reduces triglycerides 3
• Physical activity: Regular aerobic exercise

Pharmacologic Management:

The primary concern here is ASCVD risk reduction, not pancreatitis prevention 2, 1.

• Statin therapy is first-line for patients with:
  • Age 40-75 years with 10-year ASCVD risk ≥7.5% 1
  • Diabetes mellitus (regardless of age)
  • Established ASCVD
  • Age 40-75 years with 10-year ASCVD risk 5-7.5% (after shared decision-making) 1

Statins provide 10-30% dose-dependent triglyceride reduction while primarily targeting LDL-C 1.

• Consider adding triglyceride-lowering therapy if triglycerides remain ≥150 mg/dL despite maximally tolerated statin:
  • Icosapent ethyl (prescription EPA): For patients with established ASCVD or diabetes plus ≥2 additional CV risk factors 4
  • Fibrates or omega-3 fatty acids: Alternative options, though evidence for CV benefit is limited 1

Severe Hypertriglyceridemia (500-999 mg/dL)

This level carries both ASCVD risk and emerging pancreatitis risk 2, 1.

Lifestyle Interventions:

• Dietary fat restriction: 20-25% of total calories from fat (more restrictive than mild HTG) 1
• Eliminate: All added sugars and alcohol completely 1
• Increase: Soluble fiber >10 g/day
• Weight loss and exercise: As above

Pharmacologic Management:

• Initiate or maximize statin therapy for ASCVD risk reduction in appropriate patients (age ≥40 years with 10-year risk ≥5%, diabetes, or established ASCVD) 1

• Add triglyceride-lowering therapy:

  • Prescription omega-3 fatty acids (icosapent ethyl or omega-3 acid ethyl esters) 1
  • Fibrate therapy if necessary to prevent acute pancreatitis 1

Critical point: At this level, pharmacotherapy effectiveness may be limited until triglycerides are reduced below 500 mg/dL through dietary intervention 1.

Very Severe Hypertriglyceridemia (≥1,000 mg/dL)

This is a medical urgency—acute pancreatitis prevention is the primary goal 2, 1.

Immediate Lifestyle Interventions:

• Extreme dietary fat restriction: <10-15% of total calories from fat (or <20-40 g total fat/day) 1
• Some patients may require <5% of calories from fat initially until triglycerides drop below 1,000 mg/dL 1
• Complete elimination: All alcohol and added sugars 1
• Referral to registered dietitian nutritionist: Essential for individualized medical nutrition therapy 1

Pharmacologic Management:

• Fibrate therapy: First-line agent at this level 2, 1
• Prescription omega-3 fatty acids: Can be added 1
• Statin therapy: Consider once triglycerides are reduced and ASCVD risk can be properly assessed 1

Important caveat: When triglycerides are ≥1,000 mg/dL, pharmacotherapy has limited efficacy. The initial approach must prioritize extreme dietary fat restriction to bring levels below 1,000 mg/dL, at which point medications become more effective 1.

Monitoring and Follow-up

• Reassess triglycerides 4-12 weeks after initiating therapy
• Monitor adherence to both lifestyle and pharmacologic interventions
• Re-evaluate secondary causes if triglycerides remain elevated or increase
• Assess family history for genetic dyslipidemias in patients with primary hypertriglyceridemia 2

Common Pitfalls to Avoid

• Do not rely on non-fasting triglyceride measurements for diagnosis 2
• Do not start multiple medications simultaneously in severe HTG—dietary intervention must come first as drug efficacy is limited at very high levels 1
• Do not overlook secondary causes, particularly uncontrolled diabetes and medications 2, 1
• Do not use LDL-C alone for risk assessment when triglycerides are elevated—use non-HDL cholesterol or apolipoprotein B 2
• Do not delay referral to a dietitian for patients with triglycerides ≥500 mg/dL—individualized medical nutrition therapy is critical 1